GlassScriptPhysician profile
Octavio J Pinell
NPI 1730186859
$579.96
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $337 · 2020: $59.40 · 2021: $142 · 2022: $41.36.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $231.94 | 2019-2022 | |
| Allergan, INC. | $64.84 | 2019-2020 | |
| Duchesnay USA Incorporated | $64.07 | 2019 | |
| Pfizer INC. | $45.88 | 2019-2021 | |
| Astellas Pharma US INC | $40.04 | 2019-2022 | |
| Amgen INC. | $36.93 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.23 | 2019 | |
| Avion Pharmaceuticals | $15.82 | 2020 | |
| Ethicon US, LLC | $13.79 | 2019 | |
| Olympus America INC. | $12.71 | 2019 | |
| Mayne Pharma Commercial LLC | $12.43 | 2021 | |
| Lupin INC. | $11.28 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Octavio Pinell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.